Roche Pharma India, the Indian arm of the Swiss pharmaceutical giant Roche, has introduced its leading eye medication, Vabysmo, also known as faricimab, to the Indian market. This drug, unveiled by the global pharmaceutical leader in January 2022, achieved remarkable sales of $2.69 billion worldwide in 2023.
Vabysmo is specifically crafted to tackle two prevalent causes of vision impairment globally: ‘wet’ age-related macular degeneration and diabetic macular edema. It is rapidly becoming the preferred choice in treatment protocols. In India, an estimated four million individuals suffer from these two conditions.
While the exact pricing of the medication remains undisclosed, industry analysts suggest that the annual treatment cost could vary from ₹2 lakh to ₹4 lakh, depending on the patient’s specific circumstances. As reported by CNBC TV 18, Vabysmo, approved by the US Food and Drug Administration (FDA) in January 2022, is available in over 90 countries, with over two million doses administered globally.
